Details for Patent: 8,778,960
✉ Email this page to a colleague
Which drugs does patent 8,778,960 protect, and when does it expire?
Patent 8,778,960 protects LYBALVI and is included in one NDA.
This patent has thirty-one patent family members in eighteen countries.
Summary for Patent: 8,778,960
| Title: | Methods for treating antipsychotic-induced weight gain |
| Abstract: | The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient. |
| Inventor(s): | Deaver; Daniel (Franklin, MA), Todtenkopf; Mark (Franklin, MA) |
| Assignee: | Alkermes Pharma Ireland Limited (Dublin, IE) |
| Application Number: | 13/215,718 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 8,778,960
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-001 | May 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN | ⤷ Sign Up | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-001 | May 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN | ⤷ Sign Up | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN | ⤷ Sign Up | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN | ⤷ Sign Up | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-003 | May 28, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,778,960
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011293502 | ⤷ Sign Up | |||
| Australia | 2015201907 | ⤷ Sign Up | |||
| Australia | 2017200396 | ⤷ Sign Up | |||
| Australia | 2018202410 | ⤷ Sign Up | |||
| Canada | 2807965 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
